Table 1.
Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib (n = 125) in our cohort
| Characteristic | No. | % |
|---|---|---|
| Sex | ||
| Male | 64 | 51.2 |
| Female | 61 | 48.8 |
| Age at diagnosis, years | ||
| Median | 62 | |
| Range | 26–86 | |
| Ethnicity | ||
| Chinese | 100 | 80.0 |
| Malay | 14 | 11.2 |
| Indian | 3 | 2.4 |
| Others | 8 | 6.4 |
| Smoking status | ||
| Never | 95 | 76.0 |
| Former | 17 | 13.6 |
| Current | 13 | 10.4 |
| Histotype – NSCLC | ||
| Adenocarcinoma | 121 | 96.8 |
| Adenosquamous carcinoma | 1 | 0.8 |
| NOS | 3 | 2.4 |
| EGFR mutation type | ||
| Exon 19 deletion[a] | 87 | 69.6 |
| Exon 21 L858R | 27 | 21.6 |
| Others[b] | 11 | 8.8 |
| Brain metastases at baseline | ||
| No | 82 | 65.6 |
| Yes | 42 | 33.6 |
| Unknown | 1 | 0.8 |
| Starting dose of afatinib once daily (OD) | ||
| 40 mg | 62 | 49.6 |
| 30 mg | 61 | 48.8 |
| 20 mg | 1 | 0.8 |
| Unknown | 1 | 0.8 |
aE746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS
bE697Q; A763_Y764insFQEA; Double mutation; Unknown NSCLC Non-small cell lung cancer, NOS Not otherwise specified